BDX vs RMD stock comparison
Becton Dickinson & vs. Resmed · data as of November 13, 2026
Becton Dickinson & (BDX) has a market value of about $59.4B, Resmed (RMD) about $33.7B. Over their latest twelve months Becton Dickinson & had revenue of $19.5B and Resmed $5.7B.
On our five checks Resmed scores higher: 4.2 out of 5 (excellent) against 2.0 (weak).
By area, the stronger company is Resmed on value; Resmed on future growth; Resmed on track record; Resmed on financial health.
Resmed is cheaper on earnings (P/E 21.8 vs. 43.1).
Becton Dickinson & leads on 6 of the compared lines and Resmed on 18.
Side by side
| BDX | RMD | |
|---|---|---|
| Size and price | ||
| Market cap | $59.4B | $33.7B |
| Share price | $218.03 | $239.53 |
| Score | ||
| Overall score (of 5) | 2.0 | 4.2 |
| Value | 0 | 3 |
| Future growth | 2 | 4 |
| Track record | 2 | 5 |
| Financial health | 2 | 5 |
| Shareholder returns | 4 | 4 |
| Valuation | ||
| P/E (TTM) | 43.1 | 21.8 |
| Forward P/E | 17.5 | 18.9 |
| Price / free cash flow | 22.0 | 20.9 |
| Price / sales | 3.1 | 5.9 |
| EV / EBITDA | 14.3 | 15.9 |
| PEG | 2.61 | 0.83 |
| DCF value vs. price | −41% | −28% |
| Business | ||
| Revenue | $19.5B | $5.7B |
| Net income | $1.1B | $1.6B |
| Free cash flow | $2.7B | $1.6B |
| Net margin | 5.9% | 27.8% |
| Gross margin (5-yr avg.) | 44.6% | 57.9% |
| ROIC (5-yr avg.) | 4.8% | 18.9% |
| Growth | ||
| Revenue growth (1 yr) | 8.2% | 9.8% |
| Revenue growth (5 yrs, per year) | 6.3% | 12.1% |
| EPS growth (5 yrs, per year) | 16.5% | 26.3% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$16.1B | $400M |
| Dividend yield | 1.94% | 1.10% |
| Shareholder yield | 3.6% | 3.2% |
| Analysts | ||
| Upside to average target | +4% | +10% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: BDX TTM to September 30, 2026, RMD TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Becton Dickinson & or Resmed?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Resmed scores 4.2 out of 5 and Becton Dickinson & 2.0; the table shows where each one is stronger.
Is Becton Dickinson & cheaper than Resmed?
On trailing earnings, Resmed trades at a P/E of 21.8 and Becton Dickinson & at 43.1, so Resmed is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Becton Dickinson & or Resmed?
Over five years Resmed grew revenue about 12.1% a year and Becton Dickinson & about 6.3% a year.
Which pays a higher dividend?
Becton Dickinson & yields 1.94% and Resmed 1.10%.
Full Becton Dickinson & analysis → Full Resmed analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.